Main Uses and Benefits of Lactulose STADA

Lactulose STADA addresses two distinct therapeutic domains, offering supportive symptomatic assistance in conditions where patients experience physical discomfort or systemic imbalance.

This medication is commonly used to help manage symptoms associated with certain distressing conditions. Its therapeutic application generally addresses conditions presenting with systemic or localized discomfort, including chronic constipation, hepatic encephalopathy, and supportive management for painful symptomatic hemorrhoids or anal fissures.

---

Managing Chronic Constipation and Easing Defecation

Generally, the medication is applied across domains where additional symptomatic support is needed for chronic constipation, a condition characterized by groups of symptoms that may become intense or disruptive, such as difficulty and infrequency of bowel movements. It is commonly used to help with managing regular bowel function and comfort by helping to ease the physical effort during elimination. This generally contributes to easing the overall symptom load when symptoms related to physical discomfort interfere with routine activities.

Therapeutic Support for Liver-Related Cognitive Symptoms

Lactulose STADA may also be relevant in clinical settings marked by increased systemic burden, specifically for managing hepatic encephalopathy, where liver failure leads to symptoms of increased neurological activity, such as confusion. In these situations, the medication is used to help address symptom clusters that may become intense or disruptive. It supports the patient during difficult episodes by helping maintain a sense of stability when neurocognitive symptoms are more noticeable.

---

Quick Fact: Relief for Constipation and Cognitive Symptoms

This medication is primarily used to assist with infrequent, difficult bowel movements and to help manage the neurocognitive changes (like confusion) that may be associated with advanced liver disease. The primary benefit is assisting with comfortable, less difficult passage of stool.

Regulatory References

1. NIH MedlinePlus Drug Information

Who Can and Cannot Use Лактулоза Штада?

The eligibility to use Lactulose STADA is determined by specific age limits and pre-existing medical conditions, based on official regulatory prescribing information.

Approved Populations and Conditional Use

Population Group	Eligibility Status
Adults and Older Adults	Approved for both constipation and hepatic encephalopathy (HE). Long-term users (over 6 months) require periodic monitoring of serum electrolytes.
Pregnant and Breastfeeding Women	Permitted. No effects are anticipated on the fetus or newborn due to the drug's negligible systemic absorption.
Pediatrics (Constipation)	Approved for adolescents, children, and infants. Use in infants and small children must be exceptional and medically supervised to avoid disturbing the defecation reflex.

---

Absolute Contraindications (Cannot Use)

Lactulose STADA must not be used by patients with the following conditions:

• Galactosaemia or rare hereditary problems of sugar intolerance.
• Gastrointestinal (GI) Obstruction or high risk of digestive perforation.
• Acute Inflammatory Bowel Disease (e.g., Crohn's disease or Ulcerative Colitis).
• Hypersensitivity to the active substance (Lactulose).
• Undiagnosed painful acute abdominal symptoms.

️ Use Not Established

The safety and efficacy for the treatment of Hepatic Encephalopathy (HE) have not been established in the pediatric population (newborns through adolescents).

Interactions with other medicines and products

Lactulose STADA, due to its minimal systemic absorption, is associated primarily with pharmacodynamic interactions that influence systemic electrolyte balance or the local colonic environment. No documented pharmacokinetic interactions involving CYP enzymes or drug transporters are listed in official prescribing information.

---

Electrolyte-Related Interactions

Lactulose may increase the loss of potassium induced by co-administered medicinal products known to cause potassium deficiency, including thiazide diuretics, corticosteroids, and amphotericin B. A crucial implication of this effect is the potential for increased toxicity of cardiac glycosides, as their effects can be magnified by potassium deficiency (hypokalaemia).

---

Colonic pH and Efficacy

Interactions related to the colonic environment are also officially documented. Co-administration of non-absorbable antacids may inhibit the therapeutic pH drop caused by lactulose fermentation, potentially resulting in a lack of desired therapeutic effect. Furthermore, the lower colonic pH created by high-dose lactulose may lead to the inactivation of medicinal products that rely on a pH-dependent release in the colon, such as 5-ASA (mesalazine).

---

Administration Constraint

A specific administration constraint applies to the treatment of hepatic encephalopathy. The regulatory label states that the concomitant administration of other laxatives must be avoided in this setting to prevent hindering the individualization of the Lactulose dose.

How Лактулоза Штада Works

---

Osmotic Fluid Dynamics and Colonic Motility

The mechanism of Лактулоза Штада begins with its unique lack of digestibility by human digestive enzymes in the upper gastrointestinal tract. Upon reaching the colon, the disaccharide acts as a selective substrate for resident bacteria, which ferment it into osmotically active Short-Chain Fatty Acids ( SCFAs). This process significantly increases the luminal osmotic pressure, drawing water from the plasma into the colon lumen. This fluid influx causes an increase in the water content of the colonic contents, and the resulting volume increase mechanically stimulates propulsive peristaltic contractions of the bowel wall.

---

pH Reduction and Ammonia Ion Trapping

Simultaneously, the large amount of SCFAs produced by bacterial fermentation causes a marked reduction of the colonic pH (acidification). This lowered pH is critical as it drives the chemical conversion of the highly diffusible, uncharged ammonia ( NH3) into the non-absorbable, charged ammonium ion ( NH4^+). The mechanism ensures the trapped NH4^+ ion is directed toward excretion with the colonic contents, thereby reducing the flux of ammonia into the systemic circulation.

How to Use Лактулоза Штада (Lactulose)

Lactulose is primarily administered via the oral route as a solution or syrup. For managing acute episodes of hepatic encephalopathy (HE), the rectal route is an approved alternative, utilizing a retention enema. The full onset of the laxative effect typically requires 24 to 48 hours.

Official Dosing Regimens and Frequency

The required dosage is determined by the specific indication and is adjusted to achieve a therapeutic endpoint.

Indication	Standard Adult Regimen	Frequency and Pattern
Chronic Constipation	Initial dose: 15 mL to 45 mL (10 g to 30 g)	Once daily, or divided into two doses.
Hepatic Encephalopathy	Initial oral dose: 30 mL to 45 mL (20 g to 30 g)	Three to four times daily. Dosage is adjusted (titrated) to produce two to three soft stools per day.

Administration Conditions and Adjustments

The solution may be taken undiluted or mixed with liquids such as water, fruit juice, or milk to improve palatability. The single daily dose, if utilized, is generally taken at the same time each day.

Special Conditions: Sufficient daily fluid intake (1.5 to 2 liters) is advised during the course of therapy. Dosing for hepatic encephalopathy involves continuous, long-term use, while the rectal enema method is intended only until oral administration can commence. For older adults and patients with renal or hepatic impairment, no special dose recommendations are specified due to the medicine's negligible systemic absorption.

Research Evidence / Overview of Studies for Лактулоза Штада

This section outlines the structure of the clinical research that has evaluated lactulose. The text summarizes what has been studied and where limitations or uncertainties in the evidence exist, without offering medical advice or treatment recommendations.

---

Evidence for Chronic Constipation Studies

Research has explored the use of lactulose was evaluated in research exploring chronic constipation. The evidence base includes Randomized Controlled Trials (RCTs) and various meta-analyses.

Research explored outcomes related to physical discomfort and daily functioning, examining metrics like Complete Spontaneous Bowel Movements (CSBMs) and stool consistency. Studies primarily included adults and older adults. Findings describe patterns in bowel movement frequency that were observed in the studies. Evidence is limited for long-term outcomes regarding symptom patterns over time. Furthermore, the way successful treatment is defined varies across studies, and findings for comparative performance varied across studies.

---

Evidence for Hepatic Encephalopathy Studies

Lactulose was examined in research involving advanced liver disease. The research base includes various RCTs and Systematic Reviews focused on both treating acute episodes of HE and monitoring HE recurrence.

Studies monitored blood ammonia levels. Research also examined clinical outcomes, such as the resolution of HE symptoms assessed using the West Haven Criteria, and metrics related to hospitalization rates. Studies reported measurements of systemic ammonia levels that varied from control groups. Trials described patterns observed in the studies. Ethical considerations mean that true placebo-controlled trials for acute HE are rare, and open-label designs were observed in some studies.

---

Evidence Gaps and Research Uncertainty

The research base highlights areas where certainty remains low. For chronic constipation, the way success is measured varies across studies, and comparative evidence is lacking in some areas. For its use in constipation, follow-up durations were limited, and long-term effects are not fully established. Evidence for the use of lactulose in children with chronic constipation is limited.

Key Studies & References

1. Lactulose
2. Lactulose Drug Information

Common questions about Лактулоза Штада (FAQ)

Q: What is Лактулоза Штада (Lactulose Stada) used for?

Lactulose is a synthetic sugar used to treat constipation by drawing water into the colon, which softens the stool and promotes bowel movements. It is also used to treat hepatic encephalopathy, a severe liver disease complication involving confusion and changes in mental state, by reducing the amount of ammonia in the blood.

---

Q: How should I take Лактулоза Штада?

Lactulose is typically taken by mouth as a solution. The correct dose depends on the condition being treated and the patient's age and response to the medication. It can be mixed with water, fruit juice, or milk to improve the taste. For constipation, it is often taken as a single dose. For hepatic encephalopathy, the dose is usually higher and may be split into multiple daily doses.

---

Q: How long does it take for Лактулоза Штада to work for constipation?

It may take 24 to 48 hours (1 to 2 days) to produce a bowel movement when using lactulose for constipation. It is important to continue taking the medication as directed, even if you do not see immediate results.

---

Q: What are the common side effects of Лактулоза Штада?

Common side effects of lactulose include bloating, flatulence (gas), stomach cramps, and diarrhea. These side effects are generally mild and may decrease after the first few days of treatment as your body adjusts. If diarrhea is severe or persistent, it is important to speak with a healthcare provider, as the dose may need to be adjusted.

---

Q: Can I take Лактулоза Штада while pregnant or breastfeeding?

Lactulose is generally considered safe to use during pregnancy and breastfeeding because it is poorly absorbed by the body. However, it is always recommended to consult with a healthcare professional before taking any medication, including lactulose, while pregnant or breastfeeding to ensure it is appropriate for your specific health situation.

Storage and Disposal of Lactulose Solution

Lactulose solution must be stored and handled according to specific regulatory requirements to maintain its stability.

Storage Conditions

Requirement	Specifics
Temperature Range	Store at controlled room temperature, between 20 C and 25 C (68 F and 77 F).
Prohibited Conditions	The solution must not be frozen. Avoid prolonged exposure to temperatures above 30 C and direct light.
Container Rules	Keep the container tightly closed and use a child-resistant closure. Use of the original or a light-resistant container is required.
Stability Note	Extreme darkening or turbidity indicates the product is objectionable and must not be used. A slight color change is normal and does not affect the medicine.

Disposal Instructions

Unused or expired lactulose solution should be disposed of using a drug take-back program if one is available. If a take-back program is not accessible, the medicine must be mixed with an undesirable substance (such as dirt), sealed in a bag or container, and placed into the household trash. Personal information must be removed from the packaging before disposal.